Tempest: Positive Early Results for Phase 1b/2 Combination Study in First-Line Hepatocellular Carcinoma

 

• Positive randomized data with TPST-1120 combined with atezolizumab + bevacizumab compared head-to-head with atezolizumab + bevacizumab
  

• The addition of TPST-1120 resulted in a clinically-meaningful improvement in both confirmed and unconfirmed RECIST responses

• The number of patients on treatment and on study markedly favors the TPST-1120 arm

• Company to host webcast conference call today at 8:30 a.m. ET

Tempest will host a webcast conference call today, April 28, 2023 at 8:30 a.m. ET.

To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. The live webcast and audio archive of the presentation may be accessed on the investor section of the Tempest website at https://ir.tempesttx.com/. The webcast will be available for replay for 30 days.

https://finance.yahoo.com/news/tempest-announces-positive-early-results-120000195.html